Webinar | June 1, 2017

Developing Site-Specifically Modified ADCs Using A Chemoenzymatic Approach

Source: Catalent

Antibody-drug conjugates (ADCs) have become de rigueur for pharmaceutical oncology drug development pipelines. There are more than 40 ADCs undergoing clinical trials and many more in preclinical development. Get the latest on novel protein modification platform and its application to generate ADCs, including new conjugation chemistries and linkers.